Reported Earlier, Avalo Therapeutics Prices $375M Underwritten Public Offering Of 19.73M Common Shares And 1.4M Pre-Funded Warrants At $17.75 Per Share

Benzinga Newsdesk www.benzinga.com Neutral 94.3%